Market Overview - The overall valuation of the market has increased, with the Wind All A Index leading the rise, up by 2.9 percentage points in PE-TTM historical percentile[5] - The PB-LF historical percentile also saw an increase across indices, with the CSI 300 leading at a rise of 4.4 percentage points[5] Industry Insights - In the automotive sector, PE valuation increased by 1.1 percentage points, leading among industries[6] - The non-ferrous metals sector saw a significant rise in PB valuation, up by 14.0 percentage points, indicating strong performance[6] Trading Activity - Trading activity has increased, with the turnover rate rising by 26.0% for the SSE 50 index, while total transaction volume decreased by 1.25%[6] - As of September 30, 2025, the margin trading balance was 2.39 trillion yuan, reflecting a decrease of 1.25% compared to September 26, 2025[6] Company Performance - The company reported a revenue growth from 678,800 yuan in 2022 to 1,908,800 yuan in 2024, with a compound annual growth rate of 67.7%[12] - The gross profit margin improved significantly from 19.9% in 2022 to 32.7% in 2024, maintaining at 32.4% in the first half of 2025[12] Risk Factors - Risks include uncertainties in overseas economic conditions and geopolitical factors that may impact market stability[8] - Potential risks in the pharmaceutical sector include uncertainties in original IP incubation and fluctuations in consumer demand[13]

Investment Rating - The report assigns an "Accumulate" rating for the industry [1][57]. Core Insights - The company, as a wholly-owned subsidiary of Miniso Group, is the largest and fastest-growing trendy toy collection brand in China, actively building an IP matrix and significantly increasing the proportion of self-developed products [4][5]. - The global market for trendy toys is expected to reach $213.3 billion by 2030, with the Chinese market projected to grow from 82.5 billion yuan in 2025 to 213.3 billion yuan by 2030 [22][24]. - The company has established a diverse IP matrix through collaborations with top global IPs like Sanrio and Disney, enhancing its product offerings and consumer engagement [33][35]. Summary by Sections 1. Development History - The company began its trendy toy business in 2020 and has since established a comprehensive store network in mainland China, with plans to expand internationally by the end of 2024 [9]. 2. Industry Overview - The rise of emotional value and the expansion of IP influence are driving rapid growth in the pan-entertainment product industry, with the global market expected to grow from $44.8 billion in 2019 to $194.8 billion by 2030 [15][18]. - The trendy toy industry, characterized by high collectible value and driven by IP, is projected to grow significantly, with the Chinese market expected to reach 825 billion yuan by 2025 and 2,133 billion yuan by 2030 [22][24]. 3. Company Profile - The company is recognized as the largest and fastest-growing trendy toy collection brand in China, achieving a GMV of 2.4 billion yuan in 2024, with self-developed products contributing nearly 50% of revenue [32][33]. - Revenue has increased from 678.8 million yuan in 2022 to 1.9088 billion yuan in 2024, with a compound annual growth rate (CAGR) of 67.7% [32][47]. 4. Financial Analysis - The company's revenue grew from 678,800 yuan in 2022 to 1,908,800 yuan in 2024, with a CAGR of 67.7%, and a revenue of 1,360,200 yuan in the first half of 2025, representing a year-on-year growth of 58.5% [47][48]. - The gross margin has improved significantly, rising from 19.9% in 2022 to 32.7% in 2024, maintaining 32.4% in the first half of 2025 [47][49].

Investment Rating - The report assigns an "Overweight" rating to the investment banking and brokerage industry [3]. Core Insights - The high growth observed in the first half of the year is primarily attributed to base effects, with an annualized return of 3.9%, which is the highest in three years but still below the average of 4.8% from 2019 to 2021. The industry is undergoing a transformation, with leading brokers moving towards global allocation and smaller brokers seeking changes in asset allocation strategies [2][3]. Summary by Sections Revenue & Yield - In the first half of 2025, listed brokers reported a net income from proprietary trading of 76.3 billion yuan (after interest expenses), accounting for 30.9% of total revenue, marking a historical high. This represents an 80% year-on-year growth, with an incremental income of 33.9 billion yuan, mainly driven by the recovery in equity trading and proprietary business [3][4]. - The profit margin for the first half of 2025 shows an annualized yield of 3.9%, continuing a recovery trend over three years (2.4%, 3.2%, 3.6% in 2022-2024), but still below the 4.8% average from 2019-2021 [3][4]. Investment Scale - The total investment scale of listed brokers reached 6.8 trillion yuan by the end of the period, with a net increase of 320.6 billion yuan since the beginning of the year, excluding the effects of mergers. The increase in investments includes a rise of 348.3 billion yuan in FVTPL assets and 102.4 billion yuan in OCI equities, while AC and OCI debts decreased by 92.9 billion yuan [3][4]. - The structure of investments shows that 64% are in fixed income, 13% in equities, and 20% in products, with significant increases in cross-border fixed income and high-dividend OCI investments [3][4]. Business Model Changes - The proprietary trading model is evolving, with leading brokers expanding globally and smaller brokers adapting their asset allocation strategies. There is a notable shift towards cross-border investments and the establishment of mixed investment departments, particularly among smaller brokers [3][4]. - The report emphasizes that proprietary trading remains a pillar of the industry, necessitating transformation in the new era. It recommends prioritizing investments in brokers with significant comprehensive advantages, such as CITIC Securities and Huatai Securities, while also suggesting attention to firms with strong equity trading flexibility, like Industrial Securities and Changjiang Securities [3][4].

Investment Rating - The report rates the industry as "Overweight" [4] Core Insights - The siRNA drug industry is entering a new era with the maturation of technology platforms and the expansion of indications, focusing on the commercial value of siRNA drugs for common diseases [2][3] - siRNA drugs have transitioned from rare diseases to common diseases, showcasing strong target expansion capabilities, robust research and development extensibility, long-lasting effects, and low resistance [4][12] - The industry is witnessing a surge in business development (BD) transactions, particularly among multinational corporations (MNCs), indicating a vibrant market for siRNA technology [4][31] Summary by Sections 1. Dawn of a New Era for Small Nucleic Acid Drugs - Small nucleic acid drugs, including siRNA and ASO, are becoming a significant path for drug development, with a focus on their ability to regulate protein production [7] - The global approval of small nucleic acid drugs has reached 23, with siRNA drugs leading the way in rare disease applications [12][13] - Alnylam and other leading companies have demonstrated significant market capitalization differences due to their innovative drug development technologies [14][16] 2. Platform Characteristics and Focus on Indications - The siRNA drug industry is characterized by high barriers in modification and delivery, with a focus on breakthroughs in extrahepatic delivery systems [6][29] - The commercialization of siRNA drugs is accelerating, with multiple common diseases nearing market readiness [6][29] - The GalNAc delivery system has become the mainstream strategy for liver-targeted siRNA delivery, while breakthroughs in extrahepatic delivery are still needed [6][29] 3. Related Companies - Listed companies in the siRNA space include Yuyuan Pharmaceutical, Hengrui Medicine, and others, while unlisted companies include Bewang Pharmaceutical and others [4][12]

Group 1 - The report indicates that the A-share market is experiencing a slow bull market, with the effects of anti-involution policies becoming evident in the August PPI data, leading to continued increases in major broad-based indices in September [1][8] - The report suggests a shift towards growth-oriented investment strategies while maintaining a balanced overall style in fund allocation, with recommendations to consider gold and US stock-related ETFs [1][8] - Structural investment opportunities are highlighted, particularly in emerging technologies and financial sectors, with expectations for new highs in A/H share indices [1][8][13] Group 2 - The report notes that the manufacturing PMI for September is at 49.8%, reflecting a seasonal increase, while the service sector shows a slight decline, indicating a mixed economic outlook [10][11] - The report emphasizes the importance of the lithium battery sector, which is benefiting from favorable policies and a surge in overseas demand for energy storage, contributing to strong performance in related industries [8][10] - The report identifies a positive trend in the AI sector, with significant collaborations and advancements, suggesting continued growth potential in technology-related investments [8][10] Group 3 - The bond market is expected to enter a stabilization phase in October, with a likelihood of oscillation and potential recovery in certain bond types, despite a long-term weakening trend [17][20] - The report highlights the central bank's active role in maintaining liquidity and supporting the bond market, particularly during the quarter-end period [18][20] - The report suggests that the demand for high-grade, liquid credit bonds remains strong, with a focus on flexible duration products [17][20] Group 4 - The report indicates that the number of new funds launched in September reached the highest level since 2022, with a total fundraising amount of 167.34 billion, reflecting a recovery in the public fund market [56][60] - The report notes that equity funds accounted for a significant portion of new fund launches, indicating a growing investor interest in equity investments amid a recovering A-share market [56][60] - The report highlights the performance of various fund styles, with growth-oriented funds outperforming balanced and value funds, particularly in the TMT and midstream manufacturing sectors [48][49]

股 票 研 究 Figure 03 机器人点评 | | | Figure 03 展示家庭应用场景，为规模化生产做准备 [Table_Industry] 机器人 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 肖群稀(分析师) | 0755-23976830 | xiaoqunxi@gtht.com | S0880522120001 | | 刘麒硕(分析师) | 0755-23976666 | liuqishuo@gtht.com | S0880525080005 | 本报告导读： 究 报 告 请务必阅读正文之后的免责条款部分 行 Figure AI 推出新一代 Figure 03，依托于 Helix 系统，侧重家庭场景落地，并为规 模化生产做了设计准备，看好其后续场景落地与量产进度。 投资要点： [Table_Report] 相关报告 机器人《谷歌推出最新机器人大脑模型，1X 拟融 资 10 亿美元》2025.09.28 机器人《特斯拉计划召开人形机器人等产品量产 会议》2025.09.21 机器人《Optimus V3 量 ...

Group 1: Financial Engineering Research - The stock, bond, and gold markets showed positive, negative, and positive signals respectively as of the end of September 2025 [2] - The macro environment forecast for Q4 indicates inflation [3] Group 2: Semiconductor Equipment Industry - The U.S. House of Representatives' special committee issued a report detailing sanctions against China's semiconductor industry, suggesting measures like export controls and technology blockades to maintain U.S. dominance [4][20] - The report indicates that five major semiconductor equipment companies (AMAT, ASML, KLA, LAM, TEL) account for 80%-85% of the global market share, with China expected to spend $38 billion on semiconductor equipment in 2024 [5][21] - Despite challenges, there is optimism for domestic semiconductor equipment companies to achieve breakthroughs in core technologies, with recommended stocks including North China Huachuang and Tuo Jing Technology [4][20] Group 3: Aviation Industry - The demand for air travel surged during the National Day and Mid-Autumn Festival holidays, with domestic passenger volume increasing by over 3% year-on-year [8][29] - The aviation industry is expected to see profitability growth in Q3 2025, driven by strong public and commercial demand [9][30] - If public demand continues to recover, the Chinese aviation industry could enter a "super cycle" by 2026, with recommendations to invest in high-quality airline networks [32] Group 4: Biomedicine Industry - Heartai Medical is a leader in congenital heart disease intervention devices, with a 32.4% year-on-year revenue growth in H1 2025 [13][14] - The company is advancing biodegradable occluders, which are gaining popularity due to their clinical advantages over traditional metal devices [14] - The market for heart valve interventions in China is expected to grow significantly, with a projected CAGR of 69.8% from 2021 to 2025 [14]

Investment Rating - The report assigns an "Accumulate" rating to the company with a target price of 80.50 CNY [5][12][18]. Core Insights - The company specializes in precision components for folding machines, with expectations for continuous improvement in average selling price (ASP) per unit. The company is steadily advancing its domestic and international production capacity, enhancing its global supply capabilities [2][12][21]. - The projected revenue for the company from 2025 to 2027 is 12.37 billion CNY, 16.10 billion CNY, and 21.39 billion CNY, respectively, with net profit attributable to the parent company expected to be 1.07 billion CNY, 1.86 billion CNY, and 2.76 billion CNY [11][16][18]. Summary by Sections 1. Earnings Forecast and Valuation - The company is expected to achieve revenues of 814 million CNY in 2024, growing to 1.237 billion CNY in 2025, and 1.610 billion CNY in 2026, with a compound annual growth rate (CAGR) of 44.9% from 2024 to 2025 [11][16]. - The estimated earnings per share (EPS) for 2025, 2026, and 2027 are projected to be 0.66 CNY, 1.15 CNY, and 1.71 CNY, respectively, indicating significant growth rates of 43.3%, 73.9%, and 48.2% [11][12][18]. 2. Business Situation - The company focuses on MIM (Metal Injection Molding) and non-MIM components, with a strong presence in the supply chains of major smartphone brands, including Apple and Amazon. The company is well-positioned to benefit from the increasing demand for folding screen devices [21][22]. - The revenue from non-MIM precision components is expected to reach 460 million CNY in 2024, representing a year-on-year growth of 101.9%, driven by new projects from major clients [12][21][24]. 3. Production Capacity and Global Supply Chain - The company is making steady progress in establishing new production capacities both domestically and internationally, with factories in Changsha, Hunan, and Vietnam entering phased production [12][24].

| | 国泰海通证券 | | --- | --- | | 1 | GUOTAI HAITONG SECURITIES | | | 目 录 | | | --- | --- | --- | | | 每日报告精选（2025-09-30 09:00——2025-10-09 15:00） 3 | | |  | 宏观周报：《假期消费：表现如何》2025-10-08 | 3 | |  | 宏观周报：《假期期间：海外大事件与全球大类资产》2025-10-08 | 3 | |  宏观专题：《PMI | 边际回升：供给推动》2025-09-30 | 4 | |  | 海外策略研究：《"秋日胜春朝"——四季度港股市场展望》2025-10-07 | 5 | |  | 海外策略研究：《最近一周灵活外资或有明显回流》2025-10-07 | 6 | |  | 行业跟踪报告：纺织服装业《Nike FY26Q1 北美、跑步引领修复趋势，大中华仍需耐心》2025-10-09 | 7 | |  | 行业月报：医药《景气延续，继续推荐创新药械产业链》2025-10-09 | 7 | |  | 行业跟踪报告：半导体设备《自强，先进制 ...

- The high-frequency skewness factor showed strong performance with long-short returns of 0.9%, 4.93%, and 22.69% for the past week, September, and 2025, respectively[5][9] - The intraday downside volatility proportion factor had long-short returns of 0.77%, 5.18%, and 18.23% for the past week, September, and 2025, respectively[5][9] - The post-open buying intention proportion factor had long-short returns of 1.11%, 3.65%, and 19.98% for the past week, September, and 2025, respectively[5][9] - The post-open buying intention intensity factor had long-short returns of 1.62%, 3.28%, and 25.81% for the past week, September, and 2025, respectively[5][9] - The post-open large order net buying proportion factor had long-short returns of 0.34%, 1.51%, and 20.7% for the past week, September, and 2025, respectively[5][9] - The post-open large order net buying intensity factor had long-short returns of 0.38%, 1.51%, and 12.86% for the past week, September, and 2025, respectively[5][9] - The intraday return factor had long-short returns of 0.98%, 1.26%, and 20.66% for the past week, September, and 2025, respectively[5][9] - The end-of-day trading proportion factor had long-short returns of 1.25%, 4.18%, and 17.74% for the past week, September, and 2025, respectively[5][9] - The average single outflow amount proportion factor had long-short returns of 0.29%, 0.26%, and -0.54% for the past week, September, and 2025, respectively[5][9] - The large order-driven price increase factor had long-short returns of 0.09%, 2.88%, and 8.88% for the past week, September, and 2025, respectively[5][9] - The GRU(10,2)+NN(10) deep learning factor had long-short returns of 1.33%, 8.73%, and 41.75% for the past week, September, and 2025, respectively, with long-only excess returns of 0.71%, 3.42%, and 8.08%[5][9] - The GRU(50,2)+NN(10) deep learning factor had long-short returns of 1%, 7.98%, and 42.75% for the past week, September, and 2025, respectively, with long-only excess returns of 0.63%, 2.99%, and 7.91%[5][9] - The multi-granularity model (5-day label) factor had long-short returns of 0.99%, 6.15%, and 53.09% for the past week, September, and 2025, respectively, with long-only excess returns of 0.5%, 2.56%, and 19.48%[5][9] - The multi-granularity model (10-day label) factor had long-short returns of 0.81%, 5.2%, and 49.1% for the past week, September, and 2025, respectively, with long-only excess returns of 0.37%, 2.97%, and 20.1%[5][9] - The weekly rebalanced CSI 500 AI enhanced wide constraint portfolio had excess returns of -0.99%, -4.8%, and -0.06% for the past week, September, and 2025, respectively[5][11] - The weekly rebalanced CSI 500 AI enhanced strict constraint portfolio had excess returns of -1%, -2.32%, and 2.66% for the past week, September, and 2025, respectively[5][11] - The weekly rebalanced CSI 1000 AI enhanced wide constraint portfolio had excess returns of -1.48%, -1.06%, and 7.53% for the past week, September, and 2025, respectively[5][11] - The weekly rebalanced CSI 1000 AI enhanced strict constraint portfolio had excess returns of -0.79%, -0.12%, and 13.11% for the past week, September, and 2025, respectively[5][11]